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Abstract
Background: Myxovirus resistance protein A (MxA) is a molecule induced after interferon-beta injection, mostly used to
evaluate its bioactivity. There is little available data on clinical utility of baseline MxA mRNA status. The objective of the
study is to investigate whether baseline MxA mRNA expression can predict relapse and disease progression in multiple
sclerosis patients treated with interferon-beta.
Methods: Baseline blood samples were obtained before the first interferon-beta dose was administered to evaluate MxA
mRNA expression using real-time polymerase chain reaction (PCR). Demographic and clinical variables were prospectively
recorded to define treatment responder and non responder groups.
Results: 104 patients were included in the study. Baseline MxA mRNA expression was significantly lower in the group of
patients who met the definition of responders (1.07 vs 1.95, Student t test, p,0.0001). A threshold of 1.096 was established
using Receiver Operating Characteristic analysis to differentiate between responders and non-responders (sensitivity 73.9%,
specificity 69.0%). Survival analysis using this threshold showed that time to next relapse (p,0.0001) and to EDSS
progression (p = 0.01) were significantly higher in patients with lower MxA titers.
Conclusion: The results suggest that baseline MxA mRNA levels may be useful for predicting whether multiple sclerosis
patients will respond or not to interferon-beta treatment.
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Multiple sclerosis (MS) is an immune-mediated demyelinating
disease of the central nervous system that mainly affects middle-
aged adults and is a common cause of disability. Several therapies
are available for the treatment of MS. Interferon beta (IFN-b) was
the first approved and is one of the most common immunomod-
ulatory therapies used for this condition. Results from clinical trials
have shown a reduction in the MS relapse rate of about 30% with
this agent [1–6]. Unfortunately, not all patients respond properly
to MS therapies. A percentage of patients do not respond to
treatment, and this fact could only be recognized after months or
years of therapy. It would be of value being able to determine
whether a patient will respond to each type of treatment so that
the most appropriate therapy can be given before the disease
relapses or progresses.
Myxovirus resistance protein A (MxA) is a molecule induced
after injection of IFN-b, and its quantification could be considered
a biomarker of IFN-b bioactivity [7]. There is little available data
on MxA mRNA baseline status or its potential usefulness for
indicating IFN-b treatment response. The objective of this study is
to investigate whether MxA mRNA baseline expression has a role
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in predicting the occurrence of relapses or disease progression in
MS patients treated with IFN-b.
Methods
Study Design
A prospective, observational, open-label, non-randomized study
was performed in the Multiple Sclerosis Unit of Hospital
Universitari de Bellvitge. Our MS clinic is the reference center
for demyelinating diseases in the health district of Gerència
Territorial Barcelona Metropolitana Sud in Catalonia, a region in
the northeast of Spain.
Ethics Statement
The study was approved by the Ethics Committee of Hospital
Universitari de Bellvitge, and written informed consent to
participate was obtained from each patient and control.
Patients
Patient enrollment began in February 2008 and was completed
in March 2011. Patients meeting the following inclusion criteria
were prospectively selected: treatment-naı̈ve, relapsing-remitting
MS patients fulfilling the 2005 revised McDonald criteria [8] and
achieving criteria to start IFN-b treatment. After selection, patients
initiated treatment with one of three IFN-b products: IFN-b 1a
30 mg by intramuscular administration once weekly (Avonex),
IFN-b 1a 44 mg subcutaneously three times weekly (Rebif44), or
IFN-b 1b 8 million IU subcutaneously every other day (Betaferon/
Extavia). Patients were not randomized to treatment. Therapy for
each case was selected according to guidelines for MS and the
standard medical practice in our center. Prospective follow-up was
completed in May 2012. Treatment changes were not allowed
during the study. For the development of survival curves, follow-
up was finished when a relapse or increase in the EDSS score
occurred. Patients that finished the follow-up before any of these
events occurred or stopped the treatment, were censored for that
analysis.
A cohort of non-MS controls was selected to perform gene
standard curves (MxA and GAPDH) and to normalize MS patient
samples.
Clinical assessment including the Expanded Disability Status
Scale (EDSS) [9] was performed every 6 months following the start
of treatment and at the time of relapse. Clinical, demographic and
radiological data were recorded prospectively using the European
Database for Multiple Sclerosis (EDMUS) [10]. Relapses were
established based on the development of a new symptom or
worsening of an old symptom attributable to MS, accompanied by
consistent neurological dysfunction lasting at least 24 hours in the
absence of fever and preceded by stability or improvement for at
least 30 days [11]. EDSS progression was defined as an increase of
at least 1 point on the EDSS score. The EDSS score had to be
confirmed at least 6 months later to be defined as irreversible [12].
Treatment responders (R) and non-responders (NR) were
defined as follows: Responders were patients presenting no
relapses or EDSS progression during follow-up. Non-responders
were those presenting relapses and/or EDSS progression. Two
groups were defined in the non-responders group: Relapse-NR
were patients presenting relapses but no increase on the EDSS
score and EDSS-NR comprised of patients presenting EDSS
progression or relapses and additionally EDSS progression at
follow-up.
Samples
Blood samples were obtained before the first IFN-b dose and
after 12 months of treatment, in the absence of signs of infection or
corticosteroid treatment for relapse. Ten milliliters of peripheral
blood from MS patients and controls was collected in an EDTA
tube. Mononuclear cells were separated on a Ficoll-Hypaque
density gradient. RNA extraction was performed with Ultraspec-II
RNA isolation system (Biotecx Laboratories, Texas, USA)
following the manufacturer’s instructions.
Complementary DNA was prepared by reverse transcription
using M-MLV Reverse Transcriptase (Invitrogen Life Technolo-
gies, Carlsbad, USA) according to the manufacturer’s recommen-
dations. Real-time PCR was performed on a Light Cycler 480
system (Roche, Mannheim, Germany) using the Lightcycler 480
sybr green master kit (Roche, Mannheim, Germany). Results were
normalized to the expression level of the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) housekeeping gene to avoid
differences due to possible RNA degradation or variable reverse
transcription efficiency. Primers for MxA and GAPDH were
designed following the description provided by other authors [13].
Standard curves were performed for each primer using control
samples diluted to different concentrations. A sample from these
curves was used as a standard and run in each experiment. Results
obtained were normalized to a calibrator. A pool of healthy
control samples was used as a calibrator and run during each PCR
assay. MxA and GAPDH PCR quantities were determined using
these standard curves and were normalized to GAPDH and to a
calibrator. Results were expressed as MxA mRNA expression
levels relative to GAPDH expression levels.
Statistical analysis
Differences in baseline clinical characteristics were analyzed
using the Student t test, chi-square test, or Mann-Whitney U test,
as appropriate. Baseline MxA mRNA expression in the R and NR
groups was compared using the Student t test. The optimal cut off
value for MxA expression was determined using receiver operating
characteristics (ROC) analysis. Kaplan Meier survival curves were
carried out to study time to the next relapse and to progression of
disability. Results obtained from baseline samples were used to
establish the cut-off to determine the presence of MxA mRNA
induction at month 12. The threshold was defined as mean + 3SD.
[14-16] Kaplan Meier survival curves were performed to study
differences in time to the next relapse and in time to progression of
disability between MxA induced and non induced patients.
All statistical analyses were performed with the Statistical
Package for the Social Sciences, 20.0 (SPSS Inc., Chicago, USA).




A total of 104 relapsing-remitting MS patients were included in
the study. The inclusion period was completed in March 2011 and
follow-up in May 2012. The patients’ baseline clinical and
radiological characteristics are shown in Table 1. No statistical
differences regarding these characteristics were found.
Responders and non-responders
At the end of follow-up, 58 (55.8%) patients met the definition
of responders and 46 (44.2%) patients were classified as non-
responders. The 46 patients in the NR group were Relapse-NR
and 16 (15.3%) EDSS-NR. None of the patients developed a
secondary progressive MS during the study, thus the 16 patients in
Baseline MxA mRNA in Multiple Sclerosis Patients
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the EDSS-NR group with confirmed EDSS progression also had
relapses.
Baseline MxA expression
The mean baseline MxA mRNA expression level was signifi-
cantly higher in the NR group (1.95, SD 1.32) than in the R group
(1.07, SD 0.86) (Student t test, p,0.0001). ROC analysis was
performed to establish a cut-off value for MxA mRNA expression
that could differentiate between R and NR. A cut-off of 1.096
yielded the best sensitivity (73.9%) and specificity (69.0%) values
(area under the curve = 0.732). The positive predictive value was
76.9% and the negative predictive value, 65.4%.
Patients were then classified as high-MxA or low-MxA
according to whether MxA mRNA levels were above or below
1.096. The baseline characteristics of the high-MxA and low-MxA
groups were analyzed, and no statistical differences were found.
(Table 1) Mean relapse rate during the study was 1.23 (SD 1.28) in
the high-MxA group and 0.46 (SD 0.99) in the low-MxA group,
(Student t test, p = 0.001). There were no differences in the
duration of study follow-up between the two groups (years, median
1.98, IQR 1.52–2.58 vs 1.74, IQR 1.04–2.90, respectively) (Mann-
Whitney U test, p = 0.554).
Fourteen patients abandoned or changed treatment before a
relapse or EDSS progression occurred: 9 interrupted treatment for
pregnancy intention, 3 switched treatment because of adverse
events (2 intense flu-like symptoms, 1 persistent lymphopenia), 1
had problems with the injector handling, and 1 abandoned
therapeutic intervention. Median follow-up in the study for these
patients was 1.29 years (IQR 0.78–1.91). There were no
differences between the groups regarding the number of patients
who did not complete follow-up (6 high-MxA and 8 low-MxA, chi-
square test p = 0.33).
Survival analysis
Survival analysis for relapses (Fig. 1) and EDSS progression
(Fig. 2) was performed using the 1.096 threshold. In the low MxA
group, the time to the next relapse and to increase one point on
the EDSS scale confirmed at 6 months was significantly longer
compared with the high MxA group (25% of patients experienced
the next relapse (percentile 75) in 2.14 years in the low-MxA group
vs 0.40 years in the high-MxA group, log-rank p,0.0001)(25% of
patients experienced EDSS progression (percentile 75) in unde-
fined time in low-MxA group vs 2.09 years in the high-MxA
group, log-rank p = 0.01).
Table 1. Clinical and demographic baseline characteristics.
High-MxA (MXA .1.069) Low-MxA (MXA ,1.069) p TOTAL
Patients 52 52 - 104
Sex, n(%) female 39 (75.0%) 36 (69.2%) 0.51a 75 (72.1%)
Age at onset, years, mean (SD) 32.31 (8.26) 33.77 (8.41) 0.37b 33.04 (8.33)
Relapses pretreatment, mean (SD) 2.37 (1.44) 2.50 (1.61) 0.65b 2.43 (1.52)
Duration MS pretreatment, years, median (IQR) 1.53 (0.82-3.19) 1.40 (0.75–3.52) 0.59c 1.53 (0.78–3.19)
Initial EDSS score, median (IQR) 1.5 (1.0–2.0) 1.5 (1.0–2.0) 0.99c 1.5 (1.0–2.0)
Duration of follow-up, years, median (IQR) 1.98 (1.52–2.58) 1.74 (1.04–2.90) 0.55c 1.94 (1.09–2.64)
Baseline MRI
-Gadolinium enhancement 16/42 (38.1%) 17/42 (40.5%) 0. 82a 33/84 (39.3%)
-Infratentorial lesions 37/49 (75.5%) 35/49 (71.4%) 0.65a 72/98 (73.4%)
Interferon, n (%)
-Rebif44 26 (50.0%) 27 (51.9%) 53 (51.0%)
-Betaferon/Extavia 22 (42.3%) 20 (47.6%) 0.89a 42 (40.4%)




Abbreviations: EDSS: Expanded Disability Scale; IQR: interquartile range; SD: standard deviation.
doi:10.1371/journal.pone.0112758.t001
Figure 1. Survival curve for the time to the next relapse using
the 1.096 threshold. Patients belonging to the low-MxA group
(MxA ,1.096) showed a significantly longer time to the next
relapse (p,0.0001).
doi:10.1371/journal.pone.0112758.g001
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MxA induction
Evaluation of MxA mRNA expression after 12 months of
treatment was performed in 96 patients. Eighteen patients showed
absence of MxA induction (defined as levels below baseline MxA
mRNA mean (1.46) +3SD (1.17) [14–16]) and in the remaining 78
patients MxA induction was demonstrated. No statistical differ-
ences were detected between high-MxA and low-MxA groups at
baseline in the proportion of patients with or without MxA
induction after one year of treatment (8 patients without MxA
induction (16.7%) and 40 with MxA induction (83.3%) after one
year of treatment in the high-MxA group at baseline vs 10 patients
without induction (20.8%) and 38 with induction (79.2%) in the
low-MxA group at baseline, Chi square test p = 0.60).
Survival analyses were performed to study differences in time to
the next relapse and to progression of disability between MxA
induced and non-induced patients at month 12. No statistical
differences were found between both groups (median time to next
relapse, MxA induced 2.93 years vs MxA non-induced 2.32 years,
log rank p = 0.72; median time to EDSS progression, MxA
induced undefined time vs MxA non-induced undefined time, log
rank p = 0.21).
Discussion
Approximately 30% to 50% of MS patients do not respond to
IFN-b treatment [12,17]. Two main types of mechanisms in the
failure to respond to IFN-b treatment have been described [18].
The first one is in part a consequence of differing baseline
characteristics, leading to interindividual differences in the
response to this drug. The baseline characteristics of IFN-induced
gene expression that conform to the so-called IFN signature [18–
20], are factors that could explain these differences. High
endogenous expression of these genes has been demonstrated in
a subgroup of patients, referred to as IFN-high. Several authors
have studied the implications of the IFN signature in the IFN
response. The results suggest that when the type I IFN pathway is
fully activated at baseline (IFN-high), there is a lack of pharmaco-
logical effect due to a loss of the ability for further stimulation by
IFN-b administration [19,21,22]. The IFN signature, and
therefore the MxA as one of the genes constituting the IFN
signature [19,20], could have a potential role as a biomarker of the
IFN-b response.
A second mechanism in the failure to respond to IFN-b therapy
is probably due to immunogenic factors leading to a decrease in
the bioavailability of IFN-b. Development of NAbs is one of the
main types but also others as the presence of different IFN
receptor isoforms could contribute to this decrease [23]. Indepen-
dently of the mechanism involved, a reduction of the expression of
induced interferon responsive genes is detected including the MxA
expression.
The present study evaluates if baseline MxA could have a role in
predicting the IFN-b response. The results suggest that baseline
MxA mRNA status can predict whether patients will respond or
not to IFN-b before starting treatment. Previously published
results suggest that patients with a less activated endogenous type I
IFN pathway would have greater ability to up-regulate genes levels
after the start of IFN, which would lead to a favorable response
[19,20]. We hypothesize that patients with low baseline MxA
status, as one of the genes involved in the IFN signature, would up-
regulate MxA levels when IFN is started and therefore would have
a favorable response. On the other hand, high MxA titers at
baseline would indicate an innate activation of genes related to
IFN response and a less inducible pathway, which would result in
failure to respond to IFN-b treatment.
Baseline MxA expression has been evaluated in several studies.
Some authors have suggested that spontaneous MxA mRNA levels
in MS patients may be useful to identify patients with active
disease forms [24] and those experiencing a relapse [25].They
found that higher baseline MxA mRNA levels are related to a
longer time to a new relapse. Essential differences were found
between these studies and the present. The objective of our study
was to evaluate if baseline MxA expression has a role in predicting
the response to IFN-b treatment while in Van der Voort study
[26] the main objective was to evaluate if MxA is related to clinical
disease activity in early MS untreated patients. Since the objectives
are different, the populations included were also different: in our
study, a homogeneous cohort of treatment naı̈ve relapsing-
remitting MS patients with at least one relapse in the previous
year and achieving criteria to start treatment was selected to
evaluate clinical response after beginning IFN-b treatment. In van
der Voort study, patients presenting with a clinically isolated
syndrome suggestive of MS or recently diagnosed with relapsing-
remitting MS were recruited. In the subgroup of 50 patients that
started treatment with INF-b, no differences in baseline MxA
mRNA levels were found between responders and non-responders,
probably due to the small sample of patients as themselves suggest.
It could be possible that untreated MS patients with low baseline
MxA levels would have more chance to experience a relapse
earlier and, at the same time, would have greater ability to induce
MxA and therefore to show a better response to the treatment with
IFN-b. Similarly, another study did not find differences between
endogenous type I IFN signature and disease course in MS treated
patients even though the patients on the high IFN signature group
showed weaker biologic response within the first treatment month
[22].
These studies provide evidence of the role of baseline
characteristics as determinants of the treatment response. The
data presented in this study support that role and indicate that
MxA may be a useful biomarker of IFN-b response in naı̈ve
relapsing-remitting MS patients. Patients with MxA levels under
the threshold take longer to relapse and to increase by one point
on the EDSS scale, likely because a less activated IFN pathway
Figure 2. Survival curve for the time to EDSS progression using
the 1.096 threshold. Patients belonging to the low-MxA group
(MxA ,1.096) showed a significantly longer time to increase by one
point on the EDSS scale (p = 0.01). doi:10.1371/journal.pone.0112758.
g002
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have greater ability to be stimulated when IFN-b treatment is
started. Nonetheless, these findings should be validated in other
MS cohorts. Our population only included treatment-naı̈ve
relapsing-remitting MS cases. The predictive performance of
MxA should be tested in other forms of MS, such as the secondary
progressive type, and in clinically isolated syndromes, and it would
be interesting to see if there are differences between treatment-
naı̈ve and previously treated patients. Another issue to resolve in
MxA mRNA measurement is the considerable variability between
laboratories; hence, standardization of the technique is needed.
MxA after one year of treatment was studied in order to
evaluate the bioavailability of IFN-b. One of the main causes of
IFN bioavailability reduction is the development of NAbs that
generally appear after 6-18 months of treatment [14,15,27]. In our
study, only 18 patients failed in MxA induction after 12 months.
Absence of MxA induction at month 12 was not related with
baseline MxA levels. This suggests that, in our population, baseline
MxA expression couldn’t predict which patients were going to
develop NAbs (evaluated through the absence of MxA induction at
month 12). Therefore, the appearance of NAbs would be better
related to the immunogenicity of the preparation, dosing
frequency and route of administration [28] than to the baseline
MxA levels. The survival analyses to study time to next relapse and
to progression of disability didn’t show differences between the
induced and non-induced patients. Presence of NAbs may explain
treatment failure after one year of treatment. Other biological
mechanisms, such as the presence of soluble IFN receptors, could
explain early treatment failure when NAbs are absent.
Over the last decades, IFN-b has been one of the most widely
used treatments for MS. New therapies with better efficacy results,
but also greater potential side effects, are now emerging. The
development of biomarkers to decide whether one or another
treatment is the most appropriate for each individual patient has
become one of the principal objectives during the last years.
Baseline MxA status had a positive predictive value of 0.77 and a
negative predictive value of around 0.65 using the cut-off defined
in this study. In conclusion, our results suggest that baseline MxA
mRNA levels may be useful for predicting whether patients will
respond or not to IFN-b, and this capability could be clinically
useful for deciding on the most appropriate therapy option.
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interferon signature in monocytes is associated with poor response to interferon-
B in multiple sclerosis. Brain 132: 3353–3365.
20. van Baarsen L, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, et al.
(2008) Pharmacogenomics of interferon-B therapy in multiple sclerosis: baseline
IFN signature determines pharmacological differences between patients. PLos
One 3(4): e1927. Available: http://www.plosone.org/article/info%3Adoi%2F10.
1371%2Fjournal.pone.0001927 Accessed April 02, 2008.
21. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, et al. (2010) T
helper type I and 17 cells determine efficacy of interferon-beta in multiple
sclerosis and experimental encephalomyelitis. Nat Med 16: 406–412.
22. Hundeshagen A, Hecker M, Paap BK, Angerstein C, Kandulski O, et al. (2012)
Elevated type I interferon-like activity in a subset of multiple sclerosis patients:
molecular basis and clinical relevance. J Neuroinflammation 9: 140. Available:
http://www.jneuroinflammation.com/content/9/1/140 Accessed 22 June
2012.
23. Sottini A, Capra R, Serana, Chiarini M, Caimi L, et al. (2009) Interferon-Beta
therapy monitoring in multiple sclerosis patients. Edcr Metab Immune Disord
Drug Targets 9: 14–28.
24. Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, et al. (2002) Low
expression of interferon-stimulated genes in active multiple sclerosis is linked to
subnormal phosphorylation of STAT1. J Neuroimmunol 129: 205–215.
25. Hesse D, Krakauer M, Lund H, Ryder LP, Alsing I, et al. (2007) Spontaneous
MxA mRNA expression is associated with low MRI disease activity in multiple
sclerosis. Mult Scler 13: S37–S38, p143.
Baseline MxA mRNA in Multiple Sclerosis Patients
PLOS ONE | www.plosone.org 5 November 2014 | Volume 9 | Issue 11 | e112758
26. Van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BM, et al.
(2010) Spontaneous MxA mRNA level predicts relapses in patients with recently
diagnosed MS. Neurology 75: 1228–1233.
27. Serana F, Imberti L, Amato MP, Comi G, Gasperini C, et al. (2014) MxA
mRNA quantification and disability progression in interferon beta-treated
multiple sclerosis patients. PLoS One 9(4): e94794. Available: http://www.
plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0094794. Ac-
cessed 2014 Apr 14.
28. Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, et al. (2007)
Interferon beta preparations for the treatment of multiple sclerosis patients differ
in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13:
208–214.
Baseline MxA mRNA in Multiple Sclerosis Patients
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e112758
